Fig. 3From: Efficacy and safety of the novel GlyT1 inhibitor BI 425809 in Alzheimer’s dementia: a randomized controlled trialChange from baseline* in ADAS-Cog11 total score at both week 4 and week 12 (A) and at week 12 only (B): MMRM treatment comparison. *Decreases from baseline indicate improvements in ADAS-Cog11. ADAS-Cog11, Alzheimer’s Disease Assessment Scale-Cognitive Subscale 11; CI, confidence interval; MMRM, mixed model repeated measures; QD, once dailyBack to article page